Selective Estrogen Receptor Degraders (SERDs) for Metastatic …
WEBMar 27, 2024 — SERDs are hormone therapies used to treat some hormone receptor-positive metastatic breast cancers in postmenopausal women. When a SERD is taken in pill form (orally), it may be called an oral SERD. Learn more about fulvestrant and other hormone therapies for metastatic breast cancer.
The Next-Generation Oral Selective Estrogen Receptor Degrader ...
WEBDec 1, 2023 — Camizestrant is a next-generation SERD for the treatment of ER + breast cancer, acting as a pure ER antagonist and selective ERα degrader. Camizestrant's mechanism of action stops the transcription of ER target genes in wild-type (blue) and mutant (green) ERα, impairing tumor cell proliferation.
Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose …
WEBFeb 15, 2021 — Background: AZD9833 is an oral selective estrogen receptor (ER) antagonist and degrader (SERD) in Phase 2 clinical development for the treatment of ER+ HER2− breast cancer. Here we report data from Parts C and D of the ongoing Phase 1 study (SERENA-1) examining AZD9833 in combination with palbociclib, together with updated data from Parts A ...
Oral SERDs changing the scenery in hormone receptor positive …
WEBThe intramuscular administration and modest efficacy of fulvestrant, the first SERD, triggered development of oral, more potent SERDs. This narrative review gives an overview of the current evidence regarding this new drug class.
The oral selective oestrogen receptor degrader (SERD) …
WEBDec 17, 2018 — The oestrogen receptor (ER) is an important therapeutic target in ER-positive (ER+) breast cancer. The selective ER degrader (SERD), fulvestrant, is effective in patients with metastatic breast...
Oral Selective Estrogen Receptor Degraders for Breast Cancer: Two ...
WEBJul 5, 2023 — In the phase 2 SERENA-2 trial, the oral SERD camizestrant improved PFS when compared with fulvestrant monotherapy in 240 postmenopausal women with advanced breast cancer who experienced disease progression after at least 1 ET.
Efficacy of a novel orally active SERD AZD9496 against hormone ...
WEBSep 1, 2020 — To overcome this shortcoming of an injectable drug, a novel orally active antiestrogen, AZD9496 was developed. In addition to being orally active, AZD9496 is designed as a selective ERα downregulator (SERD).
Selective Estrogen Receptor Degraders (SERDs): A Promising …
WEBNov 2, 2020 — Unfortunately, 30–50% of ER positive tumors become resistant to SERM/AI treatment after 3–5 years. Fulvestrant, the only approved selective estrogen receptor degrader (SERD), is currently an important therapeutic approach for the treatment of endocrine-resistant breast cancers.
Efficacy of a novel orally active SERD AZD9496 against hormone
WEBAZD9496 was also compared to fulvestrant in vitro as a single agent or in combination with anastrozole. Our current study shows that AZD9496 is equally effective as fulvestrant at controlling the growth of hormone sensitive human breast cancer tumors.
An emerging generation of endocrine therapies in breast cancer: a ...
WEBApr 5, 2023 — The new generation of drugs includes selective estrogen receptor modulators (SERMs), orally administered selective estrogen receptor degraders (SERDs), as well as more unique agents such as...